Navigation Links
Plasma protein Therapies Association Focuses Attention on Donors and Facilities
Date:8/19/2009

Texas Lawmakers Proclaimed August as "Plasma Protein Therapies Month"

Texas (Vocus) August 19, 2009 -- The contributions of voluntary plasma donors and the issue of treating critically ill patients with plasma protein therapies was recognized by Texas lawmakers in June when they proclaimed August "Plasma Protein Therapies Month" in the Lone Star State.

"Patients requiring plasma protein therapies have serious diseases and disorders and need to be assured that they will continue to have access to those treatments," said Josh Penrod, Vice President, Source for the Plasma Protein Therapy Association. "The collection of high-quality plasma from dedicated donors, like those in Texas, is a crucial component in the production of these therapies."

Plasma protein therapies include a treatment for primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, also known as genetic emphysema, and for blood clotting disorders such as hemophilia. In addition, a plasma protein therapy is used in critical care settings, when treating severe trauma, burns and during major surgery. Plasma protein therapies refer to plasma-derived therapies and their recombinant analogs.

Hundreds of Texans each year donate plasma at 48 collection centers in Texas to help create therapies that save the lives of thousands of people across the nation. In fact, Texas has the most plasma donation centers in the nation.

This recognition raises awareness of the rare, genetic diseases treated with the therapies and to honor plasma donors across the state for their contributions to the little known treatments that benefit patients with a variety of genetic diseases and those in critical care settings including trauma and major surgery.

The Plasma Protein Therapies Association, a trade association representing plasma protein therapy manufacturers and the source plasma collection industry.

For more information about plasma protein therapies the diseases they treat and donating plasma, please go to www.donatingplasma.org or www.pptaglobal.org.

The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasma derived and recombinant analog therapies (collectively, "plasma protein therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions, and alpha 1 proteinase inhibitor used to treat people with alpha 1 antitrypsin deficiency, also known as genetic emphysema.

Contacts:
Kym H. Kilbourne
(443) 458 4682
(443) 995-2102 (cellular)

Kara Flynn
(443) 458-4669
(443) 370-1177

###

Read the full story at http://www.prweb.com/releases/plasma_donor/Plasma_Protein_Therapy/prweb2766454.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. Data From Antheras Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
7. Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars
8. China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma
9. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
10. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
11. Grifols Biomat USA Opens New Plasma Donor Center in Lincoln
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology: